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The activity of succinyl-CoA synthetase from mouse liver and kidney was inhibited by streptozotocin in 
vitro. Streptozot~in behaved essentially as a noncompetitive inhibitor, and the following kinetic values 
were obtained (in the presence of 10 nM streptozotocin): apparent X;, 1.7 mM, apparent K, 10 nM, and 
k,,, 440 nkat . kg-i. Compared with non-diabetic control mice, the succinyCCoA synthetase activity was sig- 
nificantly decreased in the islets and kidneys of mice with early (I h) and manifest (2 2 days) streptozotocin 
diabetes, whereas the activity in the liver was not significantly altered. Inhibited succinyl-CoA synthetase 
activity is believed to play a prominent role in the cellular effects of streptozotocin. 
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1. INTRODUCTION 
Streptozotocin, which chemically is a 2deoxy-2- 
(3-methyl-3-nitrosoureido)-D-glucopyranose, pos- 
sesses antibiotic, diabetogenic, antitumoral and 
tumor-inducing properties, and, besides alloxan, 
represents the most commonly used compound for 
experimental production of diabetes. The diabeto- 
genicity is related to necrosis of islet B-cells, the 
nitrosourea moiety providing the cytotoxic effect 
and the glucose moiety facilitating the entry of the 
drug into the B-cells [I]. 
The mechanism underlying the cellular effects of 
streptozotocin remains as yet unknown. According 
to one current hypothesis, the diabetogenicity is 
due to induction of DNA strand breaks and stimu- 
lated poly(ADP-ribose) synthetase activity leading 
to intracellular NAD depletion 121. The same 
h~othesis has been proposed for alloxan diabetes 
[2]. However, the biochemical changes in alloxan 
diabetes are not identical with those in streptozoto- 
tin diabetes, although there are considerable simi- 
larities. According to our hypothesis, alloxan dia- 
betes is dependent on structural and biochemical 
alterations in the mitochondria of ~loxan-sensitive 
organs, with inhibited activity of citric acid cycle 
enzymes 13-51 and disturbed Ca2+ homeostasis 
[G-10] as prominent features. Our finding of 
alloxan-induced Ca2’ release from isolated mito- 
chondria has recently been verified by others [I 11. 
Alloxan inhibits the activity of succinyl-CoA 
synthetase [3], and in our studies of different 
aspects of experimental diabetes we have observed 
that streptozotocin is a potent inhibitor of the 
activity of the same enzyme. Since this enzymatic 
inhibition might be of importance for the cellular 
effects and the diabetogenicity of streptozotocin, 
description is given here for the first time. 
2. MATERIALS AND METHODS 
Enzyme activities were determined in sonically 
disrupted, isolated mitochondria from liver and 
kidneys of 3-4-month-old C57BL-KsJ- +/+ mice 
of either sex. For in vivo experiments, streptozoto- 
tin (2OOmg/kg body wt) or saline (controls) was 
injected i.p. in KsJ mice, and for islet studies in 
ob/ob mice [4,5,7,10], and the organs were re- 
moved 1 h or 2-7 days later. Blood glucose mea- 
surements with the glucose oxidase method dis- 
closed hyperglycemia in the initial stage of diabetes 
development, and more marked hyperglycemia 
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(only animals with 218 mmol/l used here) in the 
stage of manifest diabetes. All controi mice were 
normoglycemic. The activity of succinyl-C!oA syn- 
thetase was determined at 235 nm 1121, that of 
citrate synthetase was followed at 232 nm [13], and 
that of aconitase was measured as described in [3]. 
3. RESULTS AND DISCUSSION 
The injection in experimental animals of either 
alloxan or streptozotocin results in manifest dia- 
betes, usually within 2 days, and the islet B-cells 
are structurally altered and blood glucose concen- 
tration changed already during the first hour fol- 
lowing treatment, the earliest morphological alter- 
ation being localized to the mitochondria and the 
pattern of Ca2+ -containing pyroantimonate pre- 
cipitation 10min after alloxan injection [6]. Al- 
though the development and manifestations of 
alloxan diabetes are in many ways similar to those 
of streptozotocin diabetes, there are differences in 
other respects [11, and therefore it is probable that 
the effects of these drugs on the cellular level are 
similar, but not identical. 
The rapid development of morphological and 
biochemical changes in animals treated with alloxan 
or streptozotocin points to a possible role of inhi- 
bition of essential enzymes. A preceding study dis- 
closed that alloxan inhibits the activity of most 
citric acid cycle enzymes, including citrate synthe- 
tase, aconitase and suc~inyl-CoA synthetase [3 J , 
and in vivo and additional in vitro data supported 
the finding of inhibition of mitochondrial aconi- 
tase [4,5]. 
Here, streptozotocin (IOOpM) did not alter the 
activity of mitochondrial aconitase or citrate syn- 
thetase (not shown). In contrast, streptozotocin 
markedly inhibited the activity of succinyl-CoA 
synthetase. 50% inhibition of enzyme activity was 
found at approx. IO-* M streptozotocin with en- 
zyme from both mouse liver and mouse kidney. 
Streptozoto~in behaved essentially as a non-com- 
petitive inhibitor as demonstrated in fig.1 for en- 
zyme from mouse liver. In the presence of 10nM 
streptozotocin the apparent Ki was 10 nM. The ap- 
parent K,,, was 1.7 mM, and the k,,* 440 nkat * kg- ‘. 
The values represent he means of data obtained 
from Lineweaver-Burk and Eadie-Hofstee plots 
and direct computerized calculation. 
Thus, the preceding [3] and the present data in- 
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Fig. 1. Lineweaver-Burk plot of succinyl-CoA synthetase 
activity in mouse liver mitochondria in the absence 
(o---+) and presence of 1OnM (c--+) and 1OOnM 
(@--@) streptozotocin. 
dicate that the activity of syccinyl-CoA synthetase 
is inhibited by the two most well-known diabeto- 
genie compounds detected so far. Because of the 
central role of the citric acid cycle for cellular func- 
tion, this kind of inhibition might lead to or con- 
tribute to pathological alterations, including the 
manifestations of diabetes. If this is the case, it 
ought to be possible to demonstrate inhibited en- 
zyme activity in diabetic animals also under in vivo 
conditions, not only in the manifest stage of the 
disease, but also in the initial stage, shortly after 
the injection of the diabetogenic ompound. 
Consequently we determined the activity of suc- 
cinyl-CoA synthetase in different stages of strepto- 
zotocin diabetes, using organs (islets and kidneys) 
with ‘high sensitivity’, and one organ (liver) with 
‘lower sensitivity’ to diabetogenic drugs. The data 
in table 1 show that the activity of succinyl-CoA 
synthetase was significantly decreased in the islets 
and kidneys of mice, in both the early and manifest 
stages of the disease. Although the enzyme activity 
in the liver was lower in the diabetic mice than in 
the control animals, the decrease was not statisti- 
cally significant. 
The occurrence of significant in vivo inhibition 
of enzyme activity in the islets and kidneys, but not 
in the liver, is consistent with differences among 
the organs in the sensitivity to diabetogenic om- 
pounds. Factors appear to be present in vivo which 
make the liver more resistant to diabetogenic in- 
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Table 1 
Succinyl-CoA synthetase activity in mice injected with streptozotocin (STZ) or saline (controls) 
Animal group; 
interval after 
iniection 
ld x spec. act. (AABo.mg protein-‘.min-‘) 
Liver Kidneys Islets 
Controls 29.1 f 0.9 (8) 36.6 f 1.2 (8) 32.8 + 1.4 (5) 
STZ; 1 h 25.9 f 1.0 (6) 11.1 + 0.8 (6)” 8.5 f 0.9 (3)a 
STZ; r2 days 26.5 f 1.1 (6) 3.5 f 0.4 (6)a 2.1 f 0.3 (4)= 
The substrate was 10 mM succinate. Values are means &SE with the number of observations 
given in parentheses. Statistical difference from control values by Student’s I-test: “p < 0.001 
fluences than the islets and kidneys. It should also 
be noted that there are organ differences in the in 
vivo uptake of diabetogenic ompounds [7]; higher 
concentrations of such compounds may be reached 
in organs which are freely permeable to glucose 
than in those which are dependent on insulin. 
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